These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 33601250)

  • 61. Revolutionizing Precision Oncology through Collaborative Proteogenomics and Data Sharing.
    Rodriguez H; Pennington SR
    Cell; 2018 Apr; 173(3):535-539. PubMed ID: 29677503
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Data-driven approaches to advance research and clinical care for pediatric cancer.
    Gout AM; Arunachalam S; Finkelstein DB; Zhang J
    Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188571. PubMed ID: 34051287
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Genetic Testing and Tissue Banking for Personalized Oncology: Analytical and Institutional Factors.
    Miles G; Rae J; Ramalingam SS; Pfeifer J
    Semin Oncol; 2015 Oct; 42(5):713-23. PubMed ID: 26433552
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Utility of Reverse-Phase Protein Array for Refining Precision Oncology.
    Masuda M; Yamada T
    Adv Exp Med Biol; 2019; 1188():239-249. PubMed ID: 31820392
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Differences in Conceptual Understanding of the "Actionability" of Incidental Findings and the Resultant Difference in Ethical Responsibility: An Empirical Study in Japan.
    Ibuki T; Yamamoto K; Matsui K
    AJOB Empir Bioeth; 2020; 11(3):187-194. PubMed ID: 32615058
    [TBL] [Abstract][Full Text] [Related]  

  • 66. "Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource.
    Kurnit KC; Bailey AM; Zeng J; Johnson AM; Shufean MA; Brusco L; Litzenburger BC; Sánchez NS; Khotskaya YB; Holla V; Simpson A; Mills GB; Mendelsohn J; Bernstam E; Shaw K; Meric-Bernstam F
    Cancer Res; 2017 Nov; 77(21):e123-e126. PubMed ID: 29092956
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice.
    Arnall JR; Petro R; Patel JN; Kennedy L
    J Oncol Pharm Pract; 2019 Jan; 25(1):179-186. PubMed ID: 29078708
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Precision oncology : How can high-quality healthcare remain affordable for all in the face of diagnostic and therapeutic costs?].
    Schlomm T; Rödiger T; Graalmann J
    Urologe A; 2021 Jan; 60(1):3-7. PubMed ID: 33315135
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Using a Genomics Taxonomy: Facilitating Patient Care Safety and Quality in the Era of Precision Oncology.
    Friend P; Dickman E; Calzone K
    Clin J Oncol Nurs; 2021 Apr; 25(2):205-209. PubMed ID: 33739339
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Discovery through clinical sequencing in oncology.
    Donoghue MTA; Schram AM; Hyman DM; Taylor BS
    Nat Cancer; 2020 Aug; 1(8):774-783. PubMed ID: 35122052
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.
    Chae YK; Pan AP; Davis AA; Patel SP; Carneiro BA; Kurzrock R; Giles FJ
    Mol Cancer Ther; 2017 Dec; 16(12):2645-2655. PubMed ID: 29203694
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Art and Challenges of Precision Medicine: Interpreting and Integrating Genomic Data Into Clinical Practice.
    Madhavan S; Subramaniam S; Brown TD; Chen JL
    Am Soc Clin Oncol Educ Book; 2018 May; 38():546-553. PubMed ID: 30231369
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Untangling Data in Precision Oncology - A Model for Chronic Diseases?
    Fernández XM
    Yearb Med Inform; 2020 Aug; 29(1):184-187. PubMed ID: 32823314
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations.
    Allegretti M; Fabi A; Buglioni S; Martayan A; Conti L; Pescarmona E; Ciliberto G; Giacomini P
    J Exp Clin Cancer Res; 2018 Mar; 37(1):47. PubMed ID: 29506529
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Strategies For Clinical Implementation: Precision Oncology At Three Distinct Institutions.
    Nadauld LD; Ford JM; Pritchard D; Brown T
    Health Aff (Millwood); 2018 May; 37(5):751-756. PubMed ID: 29733728
    [TBL] [Abstract][Full Text] [Related]  

  • 76. High-throughput sequencing in clinical oncology: from past to present.
    Mery B; Vallard A; Rowinski E; Magne N
    Swiss Med Wkly; 2019 Mar; 149():w20057. PubMed ID: 30946479
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Perspective on Precision Medicine in Oncology.
    Johnson TM
    Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Identification of Genomic Somatic Variants in Cancer: From Discovery to Actionability.
    Fawcett GL; Karina Eterovic A
    Adv Clin Chem; 2017; 78():123-162. PubMed ID: 28057186
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era.
    Cheng F; Hong H; Yang S; Wei Y
    Brief Bioinform; 2017 Jul; 18(4):682-697. PubMed ID: 27296652
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Establishment and implementation of Cancer Genomic Medicine in Japan.
    Mukai Y; Ueno H
    Cancer Sci; 2021 Mar; 112(3):970-977. PubMed ID: 33289217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.